You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》匯豐研究下調海吉亞醫療(06078.HK)目標價至66元 評級「買入」
阿思達克 09-06 12:47
匯豐研究發表報告,指海吉亞醫療(06078.HK)中期收入及經調整淨利潤在扣除新冠檢測影響下按年升21.1%及67.5%,略遜於該行及市場預期,受海吉亞二期項目進展慢於預期,以及非腫瘤及非必需醫療治理需求放緩影響。 該行下調對公司下半年及全年收入及盈利預測,料下半年及全年收入在扣除新冠相關影響下按年增長41%及32%,整體預期新併購的宜興及長安醫院在今年貢獻2億元人民幣收入及2,700萬元人民幣淨利潤,明年至2025年貢獻10億及13億元人民幣收入,以及1.46億及1.96億元人民幣淨利潤。當中宜興醫院自7月完成整合後已貢獻公司19%收入增長,料長安醫院第四季貢獻收入。 該行因應下調人民幣兌港元匯價預測及盈利預測,下調對該股目標價,由70元降至66元,維持「買入」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account